Please ensure Javascript is enabled for purposes of website accessibility

Organovo Holdings, Inc.'s Biggest Win in 2016

By Keith Speights - Updated Dec 13, 2016 at 6:07AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Organovo more than tripled its revenue in 2016 compared to the prior year, but its biggest win of all was something different.

This turned out to be great year for Organovo Holdings (ONVO 0.67%). Shares of the 3D-bioprinting company climbed over 30% during 2016. Organovo had several important developments during the year, but what was the company's biggest win?

Image source: Getty Images

Launch of second commercial product

In September, Organovo announced the launch of its second commercial product, ExVive human kidney tissue. This kidney tissue enables customers to study the effects of drug exposure in the human kidney as part of their drug discovery and development processes. The company's first product, ExVive human liver tissue, hit the market in 2014.

Organovo was receiving orders for its new 3D-bioprinted kidney tissue even before the launch was announced. The company said that multiple contracts had been signed, including with two of the largest pharmaceutical companies in the world.

The primary benefit to customers for using the 3D-bioprinted kidney tissue is that it can allow drugmakers to detect toxicity earlier than conventional approaches such as animal testing. This early detection can potentially save pharmaceutical companies a lot of money.

Why was this the biggest win of the year for Organovo? The addition of a second product immediately added to the company's revenue growth. It also opened up a new market that is a natural extension to Organovo's liver tissue business. Organovo's executives think that the kidney tissue business could eventually generate annual revenue of $100 million or more.

Honorable mentions

While the launch of the ExVive human kidney tissue was arguably Organovo's biggest win in 2016, the company did have several other successes. Honorable mentions go to more than tripling revenue from the prior year and to a couple of important scientific publications and presentations.

In March, Bristol-Myers Squibb (BMY -0.55%) and Organovo scientists presented data at the Society of Toxicology's annual meeting. These presentations focused on the benefits and potential of using 3D human liver tissues to detect drug-induced liver toxicity.

In July, researchers from Roche (RHHBY 0.77%) and Organovo published data in the scientific journal PLOS One. This publication discussed the effectiveness of Organovo's human liver tissue in detecting toxicity. In particular, the data compared the 3D-bioprinted liver tissue to traditional pre-clinical testing methods, including animal models. 

Although the collaborations with Bristol-Myers Squibb and Roche weren't quite as critical as the kidney tissue launch, they were nonetheless important to Organovo's future. The biggest hurdle to the company's success is resistance to adopting the new 3D tissues. Having major customers publicly endorse use of these tissues and citing data to back up why they're going do is huge.

Looking ahead to 2017

I expect Organovo to sustain its momentum in the new year. The company thinks that it will continue to grow revenue by triple-digit percentages well into the future. My hunch is that outlook will be true for 2017, at least.

Look for more presentations and publications in the new year like the ones with Bristol and Roche in 2016. The more Organovo gets the word out with solid data backing up its claims, the more traction it will get.

Organovo plans to expand its offerings to include metabolism studies. That's a smart strategy that fits well with what the company is already doing. Organovo hasn't announced a timeline for its metabolism program efforts. My prediction, though, is that its biggest win in 2017 will be the launch of this new service.  

Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Organovo Holdings, Inc. Stock Quote
Organovo Holdings, Inc.
$3.00 (0.67%) $0.02
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$74.15 (-0.55%) $0.41
Roche Holding AG Stock Quote
Roche Holding AG
$41.96 (0.77%) $0.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.